Skip to main content

Brokering Disease Databases

Cancer foundations and patient groups are developing disease DNA databases that they hope will lead to better treatments, the Wall Street Journal reports.

The Leukemia and Lymphoma Society, for example, is to embark on a three-year, $8.2 million project in conjunction with Oregon Health Sciences University, Illumina, and Intel to develop a database of genetic information from 900 acute myeloid leukemia patients, the Journal says. Such data will then be made available to companies looking to test drugs against certain targets and to help initiate clinical trials.

"We're talking about an aggressive timeline for moving this data into the clinic," OHSU's Brian Druker tells the Journal.

Similar efforts are underway by the Multiple Myeloma Research Foundation and the Michael J. Fox Foundation.

A foundation can act as an "honest broker" with "the influence and the clout" to power such work, George Mulligan, the director of translation medicine at Millennium Pharmaceuticals, tells the Journal.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.